Table 2.
Analytes | Round 1 (n = 47) | Round 2 (n = 49) | Round 3 (n = 41) | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
GM | (GSD) | % | Range | GM | (GSD) | % | Range | GM | (GSD) | % | Range | |
Serum PBDEs (ng/g lipid) | ||||||||||||
∑PBDEa | 22 | (2.7) | 100 | 2.3–290 | 23 | (2.4) | 100 | 2.7–290 | 19 | (2.1) | 100 | 2.4–210 |
BDE-28a | 0.57 | (2.3) | 66 | 0.20–4.3 | 0.60 | (2.2) | 71 | 0.20–5.1 | 0.50 | (2.2) | 66 | 0.20–3.6 |
BDE-47a | 9.5 | (2.9) | 100 | 0.60–150 | 9.9 | (2.7) | 100 | 1.3–150 | 7.6 | (2.6) | 100 | 0.90–99 |
BDE-99a | 1.8 | (3.0) | 94 | 0.20–44 | 1.9 | (3.0) | 90 | 0.20–34 | 1.7 | (2.5) | 95 | 0.20–20 |
BDE-100a | 1.8 | (3.5) | 87 | 0.20–42 | 1.9 | (3.3) | 90 | 0.20–44 | 1.4 | (3.0) | 90 | 0.20–35 |
BDE-153a | 6.4 | (3.2) | 100 | 0.60–97 | 6.7 | (3.1) | 100 | 0.70–95 | 5.3 | (3.3) | 100 | 0.10–55 |
Serum PBDEs (pg/g serum) | ||||||||||||
∑PBDEa | 130 | (2.7) | 100 | 14–1,900 | 140 | (2.7) | 100 | 15–2,000 | 120 | (2.4) | 100 | 15–1,500 |
BDE-28a | 3.5 | (2.4) | 66 | 1.3–29 | 3.7 | (2.4) | 71 | 1.3–30 | 3.3 | (2.3) | 66 | 1.3–25 |
BDE-47a | 57 | (3.0) | 100 | 3.9–990 | 59 | (2.8) | 100 | 7.3–1,000 | 48 | (2.7) | 100 | 5.5–710 |
BDE-99a | 11 | (3.0) | 94 | 1.3–290 | 11 | (3.2) | 90 | 1.3–230 | 10 | (2.6) | 95 | 1.3–140 |
BDE-100a | 11 | (3.1) | 87 | 1.3–280 | 11 | (3.4) | 90 | 1.3–300 | 8.0 | (3.1) | 90 | 1.3–250 |
BDE-153a | 38 | (3.6) | 100 | 3.9–700 | 39 | (3.1) | 100 | 4.5–580 | 36 | (2.7) | 100 | 5.3–400 |
Thio (μg/L)a | 450 | (470) | 100 | 72–2,300 | 570 | (360) | 100 | 61–1,500 | 480 | (450) | 100 | 16–1,800 |
Perchl (μg/L)a | 3.8 | (4.3) | 100 | 0.40–19 | 2.9 | (18) | 100 | 0.40–130 | 5.2 | (11) | 100 | 0.40–73 |
TT4 (μg/dL)b | 7.3 | (1.3) | 100 | 3.2–9.6 | 7.3 | (1.4) | 100 | 3.9–10 | 7.1 | (1.3) | 100 | 4.7–9.2 |
fT4 (ng/dL)a | 1.2 | (1.2) | 100 | 0.90–2.1 | 1.2 | (1.2) | 100 | 1.0–2.2 | 1.2 | (1.2) | 100 | 1.0–1.6 |
TSH (μIU/mL)a | 0.71 | (1.8) | 100 | 0.20–2.7 | 0.75 | (1.8) | 100 | 0.25–2.3 | 0.89 | (1.9) | 100 | 0.18–4.8 |
TT3 (ng/mL)a | 1.1 | (1.2) | 100 | 0.78–1.5 | 1.2 | (1.2) | 100 | 0.80–1.4 | 1.2 | (1.2) | 100 | 0.82–1.5 |
UIC (μg/L)a | 130 | (170) | 100 | 27–890 | 140 | (100) | 100 | 11–550 | 150 | (116) | 100 | 32–660 |
Urinary SGb | 1.02 | (0.007) | 100 | 1.00–1.03 | 1.02d | (0.009) | 100 | 1.00–1.04 | 1.02 | (0.007) | 100 | 1.00–1.03 |
TPO Ab (IU/mL)c | 3 | NA | 6 | < 5.0–810 | 3.0 | NA | 6 | < 5.0–680 | 3.0 | NA | 7 | < 5.0–640 |
Chol (mg/dL)b | 190 | (34) | 100 | 120–290 | 190 | (46) | 100 | 110–360 | 190 | (44) | 100 | 92–330 |
Trig (mg/dL)b | 130 | (70) | 100 | 50–340 | 130 | (71) | 100 | 42–340 | 140 | (66) | 100 | 45–290 |
Lipids (mg/dL)b,e | 620 | (110) | 100 | 450–860 | 620 | (150) | 100 | 370–1,100 | 630 | (140) | 100 | 330–1,000 |
Abbreviations: %, percent detected; BDE, bromodiphenyl ether; Chol, cholesterol; fT4, free thyroxine; GM, geometric mean; GSD, geometric standard deviation; Lipids, total lipids; NA, not applicable; SG, specific gravity; PBDE; pentabromodiphenyl ether; Perchl, perchlorate; Thio, thiocyanate; TPO Ab, thyroid peroxidase antibody; Trig, triglycerides; TSH, thyroid-stimulating hormone; TT3, total triiodothyronine; TT4, total thyroxine; UIC, urinary iodine concentration. aGeometric mean and geometric standard deviation. bMean and standard deviation. cNumber of participants who tested positive for TPO Ab in each round. dOne specific gravity measurement was missing in round 2. eTotal lipids = [cholesterol (mg/dL) × 2.27] + triglycerides (mg/dL) + 62.3. |